A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy
This study tests if two targeted cancer drugs, vemurafenib and cobimetinib, can help prepare high-risk thyroid cancer patients for radioactive iodine treatment. The goal is to make the cancer cells more responsive to the iodine therapy so it works better to destroy them.
You may be able to join if you are 18 or older, have been diagnosed with high-risk papillary, follicular, or Hurthle cell thyroid cancer with a specific gene change called BRAFV600E, and have not yet received radioactive iodine treatment.
Participants will take the study medications, undergo radioactive iodine therapy, and have regular check-ups, scans, and imaging tests for about 14 months to monitor their health.
This study is currently recruiting participants and takes place in Duarte, California, United States.
- 1Tests a combination of two targeted drugs before standard radioactive iodine therapy.
- 2Designed for adults with high-risk thyroid cancer and a specific gene mutation.
- 3Involves about 14 months of follow-up visits and imaging scans.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.